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Heerfordtʼs syndrome is a rare manifestation of sarcoidosis and is deﬁned as a combination of facial 
palsy,  parotid swelling,  and uveitis,  associated with a low-grade fever.  We report a case of Heerfordtʼs 
syndrome presenting with a high fever and increased serum tumor necrosis factor alpha (TNF-α) lev-
els.  The patient had facial palsy,  parotid swelling,  uveitis,  and swelling of the right supraclavicular 
and hilar lymph nodes.  Corticosteroid therapy was initiated,  and her symptoms soon resolved com-
pletely,  in tandem with a decrease in TNF-α serum levels.
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H eerfordtʼs syndrome falls within the spectrum of sarcoidosis,  and occurs in 2-5  of all sar-
coidosis cases [1,  2].  It is deﬁned as a combination 
of facial palsy,  parotid swelling,  and uveitis,  usually 
associated with a low-grade fever [3]; cases that 
involve all three symptoms are called “complete 
Heerfordtʼs syndrome” [4].  Heerfordtʼs syndrome 
manifests in various forms,  and cases of complete 
Heerfordtʼs syndrome are extremely rare.
　 Tumor necrosis factor (TNF-α) is thought to be 
critical in the genesis and maintenance of granuloma-
tous inﬂammation,  and a case of refractory sarcoid-
osis that responded to inﬂiximab (an anti-TNF-α anti-
body) has been reported [5].  Here,  we report a unique 
case of complete Heerfordtʼs syndrome with a high 
fever that presented with elevated serum TNF-α lev-
els.  Following corticosteroid treatment the symptoms,  
including the fever,  were improved and were found to 
be associated with decreased TNF-α levels,  suggesting 
that TNF-α levels were correlated with the disease 
activity of complete Heerfordtʼs syndrome.  The litera-
ture from 2005 to 2015 in the MEDLINE database 
was also reviewed,  based on a search for Heerfordtʼs 
syndrome and its clinicopathological presentations.
Case Report
　 A 34-year-old woman was referred to our hospital 
to evaluate blurred vision and right facial palsy.  She 
had a history of external hemorrhoids and an ovarian 
cyst with no noteworthy ﬁndings in her family history.  
She smoked one pack of cigarettes per day for 15 
years until age 31 and drank alcohol socially.  She had 
a 16-day history of blurred vision,  which had been 
diagnosed as uveitis and treated at another hospital 
with antibiotics and a corticosteroid ophthalmic solu-
tion.  After 6 days of treatment,  she developed a 
right-sided facial palsy,  which was diagnosed as Bellʼs 
palsy and treated with oral steroids,  tapered over ten 
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days (Betamethasone 3mg for 2 days,  2mg for 2 
days,  1.5mg for 2 days,  1mg for 2 days,  0.5mg for 2 
days).  However,  her symptoms improved only par-
tially.
　 On physical examination,  she was found to have 
uveitis and House-Brackmann grade III right periph-
eral facial nerve palsy.  Her parotid glands were 
swollen bilaterally,  and solid and painful to touch.  Her 
light supraclavicular lymph node was palpable.  An 
examination of her lungs and heart was normal,  as 
were other cranial nerve,  motor,  and sensory nerve 
examinations.  Her serum lysozyme (14.8 µg/mL;  
normal range: 4.2-11.5 µg/mL),  soluble IL-2 recep-
tor (1,141IU/mL; normal range: 124-466IU/mL),  
and TNF-α levels (141pg/mL; normal range: ＜2.8 
pg/mL) were elevated.  Her serum angiotensin-con-
verting enzyme,  serum,  and urinary calcium levels 
were all within normal limits.  Chest computed tomog-
raphy (CT) revealed bilateral parotid gland swelling,  
right supraclavicular,  mediastinal,  and hilar lymph-
adenopathy,  which accumulated gallium during scintig-
raphy (Fig.  1).
　 Five days after the patient arrived at our hospital,  
a percutaneous needle biopsy of her supraclavicular 
lymph node was performed,  which revealed non-suppu-
rative granulomatous lymphadenitis.  She developed a 
fever of over 38.0℃.  Seven days later,  her mediasti-
nal lymph node was biopsied via endobronchial ultra-
sound-guided transbronchial needle aspiration,  and this 
also revealed non-suppurative granulomatous lymphad-
enitis (Fig.  2).  Furthermore,  bronchoalveolar lavage 
ﬂuid revealed an elevated CD4/CD8 ratio (8.53),  
which supported the diagnosis of sarcoidosis of the 
lung.
　 Complete Heerfordtʼs syndrome was diagnosed and 
the patient was started on corticosteroid therapy with 
oral prednisolone at 30mg per day.  The following day,  
her body temperature had recovered to normal levels,  
and within 2 weeks her blurred vision and right facial 
palsy had resolved completely.  The serum TNF-α 
levels decreased to 28.1pg/mL on day 57,  and soluble 
IL-2 receptor,  lysozyme decreased to 319IU/mL,  
8.3µg/mL on day 120.  The prednisolone dose was 
reduced to 15mg for 3 months with no recurrence of 
symptoms.
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Fig. 1　 Chest computed tomography revealed bilateral parotid gland swelling,  and right supraclavicular (A),  mediastinal,  and hilar 
lymphadenopathy (B),  which displayed a high accumulation of gallium during scintigraphy (C).
Discussion
　 Heerfordtʼs syndrome was ﬁrst described in 1909 
by the Danish ophthalmologist Christian Fredrick 
Heerfordt [3].  This syndrome is a combination of 
uveitis,  parotid gland enlargement,  and facial nerve 
palsy,  usually associated with a low-grade fever.  In 
1938,  Bruins-Slot et al.  determined that this syndrome 
was associated with sarcoidosis [4],  and called cases 
that presented with all three symptoms and a low-
grade fever “complete Heerfordtʼs syndrome”.  
Darlington et al.  analyzed the manifestations of sar-
coidosis and reported that among 1,000 sarcoidosis 
patients,  only 3 (0.3 ) had complete Heerfordtʼs syn-
drome [6].
　 Our case had complete Heerfordtʼs syndrome,  
presenting with a high fever instead of a low-grade 
fever.  Serum TNF-α levels appeared to be correlated 
with the disease activity,  since the increased TNF-α 
levels decreased following corticosteroid treatment,  in 
tandem with improvements in her symptoms,  including 
her high fever.  There has been one reported case of 
complete Heerfordtʼs syndrome with increased serum 
TNF-α levels [7].  In that report,  similar to our case,  
the serum TNF-α level was over 100 pg/mL (136pg/
mL),  and tended to be higher than in general sarcoid-
osis cases (mean 26.3pg/mL,  n＝8).  To our knowl-
edge,  our case is the ﬁrst report of complete 
Heerfordtʼs syndrome in which the serum TNF-α lev-
els were evaluated both before and after corticoste-
roid therapy.
　 To analyze the various presentations of Heerfordtʼs 
syndrome,  a search of the MEDLINE database of 
literature published between 2005 and 2015 yielded 
30 articles.  After excluding those articles not speciﬁ-
cally related to Heerfordtʼs syndrome,  19 articles (21 
cases including our case) were reviewed [7-25] 
(Table 1).  The median patient age was 32 (range 
14-59) years and there were 10 males and 11 females.  
Twelve cases were described as complete Heerfordtʼs 
syndrome.  Out of the 21 cases,  only 4 presented with 
a fever ＞38℃ (Table 1-1).  Eight cases were initially 
diagnosed with another disease: Bellʼs palsy,  tem-
poromandibular joint disorder,  parotitis,  hay fever,  
Guillain-Barre syndrome,  and Sjögrenʼs syndrome.  
Most of the cases were treated with corticosteroids 
and the clinical symptoms improved,  to some extent 
(Table 1-2).
　 TNF-α is thought to generate a fever via the pro-
duction of prostaglandin E2 in the hypothalamus.  
Sweiss et al.  reported signiﬁcant associations of 
TNF-α and type I interferon serum levels with clinical 
manifestations in a sarcoidosis cohort.  They reported 
that in African-Americans,  the TNF-α levels were 
higher in those cases with sarcoidosis and a neuro-
logical disease,  compared to those patients with sar-
coidosis alone [26].  The TNF-α levels were very high 
in our case,  and improved quickly following cortico-
steroid therapy.  Therefore,  since the association of fever 
and neurological symptoms with the serum TNF-α level 
in sarcoidosis has been reported,  serum TNF-α is a 
possible biomarker for disease activity in Heerfordtʼs 
syndrome.  Recently,  TNF-α antagonists have been 
reported to advance the treatment of inﬂammatory 
arthropathies,  and are even considered for use in 
refractory sarcoidosis,  with some success [5].  Para-
275Heerfordt’s Syndrome with Elevation of TNF-αAugust 2016
A B
Fig. 2　 A needle biopsy of the right supraclavicular lymph node (A) and an endobronchial ultrasound-guided transbronchial needle aspira-
tion for the mediastinal lymph node (B) both revealed non-suppurative granulomatous lymphadenitis.
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doxically,  however,  cases of new-onset sarcoidosis-
like diseases have also been reported in patients 
receiving TNF-α antagonists [27].  Therefore,  careful 
consideration should be given to this risk when pro-
posing TNF-α antagonists for refractory sarcoidosis.
　 In conclusion,  we reported a case of complete 
Heerfordtʼs syndrome presenting with a high fever,  in 
which elevated serum TNF-α levels decreased after 
corticosteroid therapy.
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